BRAF and melanoma: Furthermore, as there is no definitive evidence that ICI therapy results in superior overall survival than anti-BRAF therapy in the adjuvant treatment of BRAF-positive melanoma, clinicians might consider anti-BRAF treatments for individuals with a high risk of irAEs (26).